Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
76 hedge funds and large institutions have $115M invested in Zynerba Pharmaceuticals, Inc in 2019 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 17 closing their positions.
823% more capital invested
Capital invested by funds: $12.5M → $115M (+$103M)
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
106% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 17
25% more funds holding
Funds holding: 61 → 76 (+15)
15% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $10.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$25.8M |
| 2 |
BlackRock
New York
|
+$11.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.98M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$7.24M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.01M |
| 2 |
CCM
Campbell Capital Management
Miami,
Florida
|
-$958K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$824K |
| 4 |
PP
PDT Partners
New York
|
-$476K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$364K |
ZYNE Hedge Fund Activity: Q2 2019 in Review
76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2019, worth a combined $115M — up 823% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ZYNE positions and 17 closed out — a net gain of 18 holders — while 22 added to existing stakes and 7 trimmed.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $25.8M. The largest seller was Susquehanna International Group, cutting an estimated $1.01M.
- 76 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2019, up from 61 in Q1 2019.
- Funds reported $115M of Zynerba Pharmaceuticals, Inc stock for Q2 2019, up 823% quarter-over-quarter.
- 35 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2019 and 17 closed out, a net change of +18 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2019 was ETF Managers Group, an estimated $25.8M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2019 was Susquehanna International Group, an estimated $1.01M sold.
Based on aggregated 13F filings for Q2 2019.